AVA-001(Adverum biotechnologies)

AVA-001（Adverum biotechnologies）

Report date: 2023/10/26 16:21:27

Base Information

Drug NameAVA-001(Adverum biotechnologies)
Drug Alias NameAVA-201rAAV.sFlt-1AVA-101AVA-001
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionVascular endothelial growth factor A inhibitorsGene transference
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsRetinal NeovascularizationMacular DegenerationRetinal Degeneration +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAdverum Biotechnologies Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAdverum Biotechnologies IncLions Eye Institute
Active IndicationsN/A
Inactive IndicationsRetinal NeovascularizationMacular DegenerationRetinal Degeneration +[4] 

Other Information

ATC CodeN/A
Related LinksN/A